Azole Resistance in Aspergillus spp., 2nd Edition

A special issue of Journal of Fungi (ISSN 2309-608X). This special issue belongs to the section "Fungal Pathogenesis and Disease Control".

Deadline for manuscript submissions: 1 October 2024 | Viewed by 400

Special Issue Editor


E-Mail Website
Guest Editor
1. Microbiology Department, Central University Hospital of Asturias (HUCA), 33011 Oviedo, Spain
2. Biosanitary Foundation for Research in the Principality of Asturias (FINBA), 33011 Oviedo, Spain
Interests: mycological diagnosis; antifungal resistance; antifungal tolerance; clinical implication of antifungal resistance; azole resistance in the environment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Aspergillus spp. fungi affect millions of patients and cause hundreds of thousands of life-threatening infections every year. Azoles have been used for many years as the main antifungal agent to treat and prevent Aspergillus spp. infections. However, these organisms can develop azole resistance in certain environments when exposed to azole compounds used as fungicides or during the long-term treatment of patients with chronic infections. Azole resistance can be devastating as almost 90% of invasive aspergillosis patients infected with a drug-resistant strain die, while chronic patients with resistant infections are administered treatments that are either poorly tolerated or less efficacious. Furthermore, some isolates show the remarkable ability to tolerate azole concentrations greater than the minimal inhibitory concentration, which may also impact clinical outcomes and act as a precursor of azole resistance. Thus, azole resistance poses a significant threat to human health with important economic implications.

This Special Issue is dedicated to Aspergillus spp. azole resistance. Among other topics, it will cover the important research and innovation needed to implement risk reduction strategies that can minimize the emergence of resistance and improve disease management.

Dr. Teresa Peláez-García de la Rasilla
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Aspergillus spp. azole resistance molecular mechanisms
  • clinical azole resistance
  • environmental azole resistance
  • evolution of azole resistance
  • detection of azole resistance
  • azole tolerance/persistence

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 563 KiB  
Review
The Role of Olorofim in the Treatment of Filamentous Fungal Infections: A Review of In Vitro and In Vivo Studies
by Aliosha Feuss, Marie-Elisabeth Bougnoux and Eric Dannaoui
J. Fungi 2024, 10(5), 345; https://doi.org/10.3390/jof10050345 - 10 May 2024
Viewed by 330
Abstract
Invasive fungal infections have recently been recognized by the WHO as a major health, epidemiological, and economic issue. Their high mortality rates and the emergence of drug resistance have driven the development of new molecules, including olorofim, an antifungal belonging to a new [...] Read more.
Invasive fungal infections have recently been recognized by the WHO as a major health, epidemiological, and economic issue. Their high mortality rates and the emergence of drug resistance have driven the development of new molecules, including olorofim, an antifungal belonging to a new family of compounds, the orotomides. A review was conducted on the PubMed database and the ClinicalTrials.gov website to summarize the microbiological profile of olorofim and its role in the treatment of filamentous fungal infections. Twenty-four articles were included from the search and divided into two groups: an “in vitro” group focusing on minimum inhibitory concentration (MIC) results for various fungi and an “in vivo” group evaluating the pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and tolerability of olorofim in animal models of fungal infection and in humans. Olorofim demonstrated in vitro and in vivo activity against numerous filamentous fungi, including azole-resistant Aspergillus fumigatus, various dermatophytes, and endemic and dimorphic fungi. in vitro results showed higher MICs for certain Fusarium species and dematiaceous fungi Alternaria alternata and Exophiala dermatitidis; further in vivo studies are needed. Published PK-PD data in humans are limited. The results of the ongoing phase III clinical trial are eagerly awaited to evaluate olorofim’s clinical impact. Full article
(This article belongs to the Special Issue Azole Resistance in Aspergillus spp., 2nd Edition)
Show Figures

Figure 1

Back to TopTop